CorMedix Inc. (CRMD)

US — Healthcare Sector
Peers: VRCA  TCRT  FENC  LRMR  VTVT  OGEN  TLPH  BPTH 

Automate Your Wheel Strategy on CRMD

With Tiblio's Option Bot, you can configure your own wheel strategy including CRMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CRMD
  • Rev/Share 1.7884
  • Book/Share 3.248
  • PB 3.4144
  • Debt/Equity 0.002
  • CurrentRatio 7.8225
  • ROIC 0.2208

 

  • MktCap 827786279.0
  • FreeCF/Share 0.4477
  • PFCF 27.2208
  • PE 14.7249
  • Debt/Assets 0.0017
  • DivYield 0
  • ROE 0.4273

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 3
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade CRMD D. Boral Capital Buy Hold -- -- June 30, 2025
Initiation CRMD H.C. Wainwright -- Buy -- $20 June 30, 2025
Initiation CRMD Leerink Partners -- Outperform -- $18 March 7, 2025
Initiation CRMD D. Boral Capital -- Buy -- $15 Jan. 13, 2025
Initiation CRMD Rodman & Renshaw -- Buy -- $13 Aug. 26, 2024

News

CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript
CRMD
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral

CorMedix Inc. (NASDAQ:CRMD ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Roanna Ruiz - Leerink Partners Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Jeevan Larson - Truist Securities John Todaro - Needham & Company Operator Good day and welcome to the CorMedix …

Read More
image for news CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript

About CorMedix Inc. (CRMD)

  • IPO Date 2010-05-13
  • Website https://www.cormedix.com
  • Industry Biotechnology
  • CEO Joseph Todisco MBA
  • Employees 64

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.